Jul 10, 2017 12:30 pm UTC| Business
JUPITER, Fla., July 10, 2017 -- Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), announced today that it has entered into a comprehensive series of research and development agreements, including a potential...
VirTra, Inc. Engages Boustead Securities as its Financial Advisor
Jul 10, 2017 12:30 pm UTC| Business
TEMPE, Ariz. and LOS ANGELES, July 10, 2017 -- VirTra, Inc. (OTCQX:VTSI), (the “Company”), a leading provider of judgmental use of force simulators and firearms training simulators, is pleased to announce that it has...
Capstone Secures Follow-On CHP Order for Three Office Towers at Melbourne CBD
Jul 10, 2017 12:30 pm UTC| Business
CHATSWORTH, Calif., July 10, 2017 -- Capstone Turbine Corporation (www.capstoneturbine.com) (Nasdaq:CPST), the world's leading clean technology manufacturer of microturbine energy systems, announced today that it has...
Impinj to Webcast Panel Discussion on RAIN RFID’s Role in Healthcare
Jul 10, 2017 12:30 pm UTC| Business
SEATTLE, July 10, 2017 -- Impinj, Inc. (NASDAQ:PI), a leading provider and pioneer of RAIN RFID solutions for identifying, locating and authenticating everyday items, today announced it will webcast a live panel...
Jul 10, 2017 12:30 pm UTC| Business
HOPKINTON, Mass., July 10, 2017 -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases,...
EXL Introduces LifePRO® Version 19 with Enhanced Management of Complex Annuities
Jul 10, 2017 12:30 pm UTC| Business
NEW YORK, July 10, 2017 -- EXL (NASDAQ:EXLS), a leading Operations Management and Analytics company, today announced Version 19 of LifePRO®, EXL's market leading policy administration platform for life, health and...
Hemispherx Updates Status of Immuno-Oncology Program in Pancreatic Cancer
Jul 10, 2017 12:30 pm UTC| Business
PHILADELPHIA, July 10, 2017 -- Hemispherx Biopharma (NYSE MKT:HEB) announced that 12 pancreatic patients are currently undergoing treatment with single-agent Ampligen immuno-oncology therapy in an Early Access Program...